Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07122713 · ClinicalTrials.gov registry record · NA
Definitive Radiation Therapy for Inoperable Breast Cancer
A NA study of Breast Cancer and Breast Adenocarcinoma, sponsored by Alexander Stessin.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07122713: Recruiting NA study of Breast Cancer and Breast Adenocarcinoma, sponsored by Alexander Stessin.
NCT07122713 is a NA study of Breast Cancer and Breast Adenocarcinoma that is actively recruiting participants, run by Alexander Stessin. The registered enrollment target is 30 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07122713, a NA study of Breast Cancer and Breast Adenocarcinoma, is actively recruiting participants, sponsored by Alexander Stessin.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if adding radiation therapy to routine medications for breast cancer helps in reducing and preventing the cancer from getting worse. Patients with a locally advanced breast cancer who cannot, or do not want to, undergo surgery are eligible to participate. Participation in this study does not prevent you from undergoing surgery in the future.
Primary Outcome
Incidence of physician-assessed treatment-related toxicity ≥ Grade 4 events, as defined using CTCAE 5.0
Conditions Studied
Interventions
- RADIATION Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor
- RADIATION Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor and ipsilateral axillary lymph nodes
Study Locations (1)
New York
- Stony Brook University Cancer Center - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-12-08 |
| Est. Completion | 2033-12-30 |
| Phase | NA |
What NCT07122713 shows while recruiting
NCT07122713 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor is the first listed.
NCT07122713 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07122713 about?
NCT07122713 is a clinical study titled "Definitive Radiation Therapy for Inoperable Breast Cancer". The purpose of this study is to find out if adding radiation therapy to routine medications for breast cancer helps in reducing and preventing the cancer from getting worse. Patients with a locally advanced breast cancer who cannot, or do not want to, undergo surgery are eligible to participate. Par...
What is the current status of trial NCT07122713?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-12-08. Estimated completion is 2033-12-30.
What conditions does trial NCT07122713 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Adenocarcinoma.
What interventions are being tested in trial NCT07122713?
The interventions under investigation include: Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor (RADIATION), Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor and ipsilateral axillary lymph nodes (RADIATION).
Who is sponsoring clinical trial NCT07122713?
This trial is sponsored by Alexander Stessin, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07122713 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07122713's enrollment target sits among peer trials
30 955th of 1224 higher than 227 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI